Michael Rosen Of DOR BioPharma Named In I-Street Magazine's Top 100 People of Chicago's High Tech Economy.

Business Editors

CHICAGO--(BUSINESS WIRE)--Jan. 30, 2002

Michael Rosen, President and Chief Operating Officer of DOR BioPharma, Inc. (AMEX: DOR), has been included in "I Street's Top 100 People of Chicago's High Tech Economy" in the January 2002 issue.

According to I-Street Magazine, the criterion for its annual list is "based on people who had impact on building a culture of entrepreneurship in the region, not just people with fancy titles who stayed holed up in their offices."

During 2001, Michael Rosen gained increasing prominence in the biotech industry as the co-chairman of the Chicago Biotech Network Association ("CBN") that recently merged with the Illinois Biotechnology Industry Organization ("IBIO"). He also helped spearhead the creation of DOR BioPharma by merging Endorex Corporation, a public company based in Lake Forest, Illinois with Corporate Technology Development, Inc., a private company based in Miami, Florida.

The Chicago Biotech Network, comprised of 150 organizations and over 200 members, is focused on helping biotechnology companies based in Chicago and the surrounding area grow and flourish. In his leadership position, Mr. Rosen has guided the growth and diversity of the organization such that it has become a vital link in the thriving Chicago biotech community. As vice-chairman, human health of the new merged association, IBIO, he will help prepare Illinois and Chicago's preparations for the BIO 2006 Annual Meeting to be held in Chicago.

Mr. Rosen was also credited in the I-Street Top 100 list for his work in creating the new company, DOR BioPharma. DOR BioPharma has two drugs in clinical development, orBec(TM) (in a Phase III multicenter clinical trial) and Oraprine(TM) (in a Phase I clinical trial). Both drugs have the potential to treat life-threatening diseases and are being shepherded through the clinical development process by Mr. Rosen.

Mr. Rosen commented, "I'm very flattered to be chosen by I-Street magazine. I think this reflects the fact that people are recognizing that Chicago is an outstanding area for nurturing first-class biotech companies."